2024
Phosphosulindac (OXT-328) prevents and reverses chemotherapy induced peripheral neuropathy in mice
Basu A, Yang J, Tsirukis V, Loiacono A, Koch G, Khwaja I, Krishnamurthy M, Fazio N, White E, Jha A, Shah S, Takmil C, Bagdas D, Demirer A, Master A, Natke E, Honkanen R, Huang L, Rigas B. Phosphosulindac (OXT-328) prevents and reverses chemotherapy induced peripheral neuropathy in mice. Frontiers In Neuroscience 2024, 17: 1240372. PMID: 38347876, PMCID: PMC10860339, DOI: 10.3389/fnins.2023.1240372.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyAnticancer effect of paclitaxelEffects of paclitaxelAllodynia scoresCold allodyniaPeripheral neuropathyInduces chemotherapy-induced peripheral neuropathyChemotherapeutic efficacy of paclitaxelLewis lung carcinoma xenograftsPrevent chemotherapy-induced peripheral neuropathyHind paw of miceAnticancer effectsTreat chemotherapy-induced peripheral neuropathyVon Frey testLevels of IL-6Chemotherapy induced peripheral neuropathyEfficacy of paclitaxelPaw of miceLung cancer xenograftsLung carcinoma xenograftsMale C57BL/6 J miceCell linesSide effects of chemotherapyEffects of chemotherapyApparent side effects
2019
The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal
Toma W, Kyte SL, Bagdas D, Jackson A, Meade JA, Rahman F, Chen ZJ, Del Fabbro E, Cantwell L, Kulkarni A, Thakur GA, Papke RL, Bigbee JW, Gewirtz DA, Damaj MI. The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. Experimental Neurology 2019, 320: 113010. PMID: 31299179, PMCID: PMC6708482, DOI: 10.1016/j.expneurol.2019.113010.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyNicotine rewardPaclitaxel treatmentRewarding effectsTreatment of CIPNPaclitaxel-induced mechanical hypersensitivityTumor-bearing NSG micePaclitaxel-induced peripheral neuropathyNon-small cell lung cancer cell linesCell lung cancer cell linesA549 non-small cell lung cancer cell lineMecamylamine-precipitated withdrawalAntitumor activityIntraepidermal nerve fibersLung cancer cell linesLung tumor growthNSCLC cell viabilityTumor-bearing miceIntrinsic rewarding effectsPlace preference testCancer cell linesConditioned place preference testMechanical hypersensitivityAgonist R
2017
Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN
Kyte S, Toma W, Bagdas D, Meade J, Schurman L, Lichtman A, Chen Z, Del Fabbro E, Fang X, Bigbee J, Damaj M, Gewirtz D. Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN. Journal Of Pharmacology And Experimental Therapeutics 2017, 364: jpet.117.243972. PMID: 29042416, PMCID: PMC5738719, DOI: 10.1124/jpet.117.243972.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPaclitaxel-induced mechanical allodyniaMechanical allodyniaPeripheral neuropathyMouse modelTreatment of CIPNLewis lung carcinoma tumor growthIntraepidermal nerve fiber lossPaclitaxel-induced peripheral neuropathyH460 non-small cell lung cancer cellsNon-small cell lung cancer cellsLung tumor cell proliferationNerve fiber dysfunctionNicotinic acetylcholine receptor subtypesCell lung cancer cellsChronic nicotine administrationNerve fiber lossChronic nicotine treatmentMale C57BL/6J miceAcetylcholine receptor subtypesLung cancer cellsProliferation of A549Receptor-mediated pathwayTumor cell proliferationCIPN treatment